SELLAS Life Sciences to Participate in Upcoming Conferences in October 2021

NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS, will participate in two upcoming conferences:

  • Laguna Biotech CEO Forum 2021 to be held at the Montage Laguna Beach hotel in Laguna Beach, CA on October 10-12, 2021.
  • A.G.P./Alliance Global Partners Biotech & Specialty Pharma Conference to be held virtually on Wednesday, October 13, 2021.

For more information about the conferences, or to schedule a one-on-one meeting with SELLAS management, please contact your representative directly, or send an email to A.G.P./Alliance Global Partners at, or KCSA Strategic Communications at

About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer (TNBC) patients, following the standard of care.

For more information on SELLAS, please visit

Investor Contacts
Allison Soss
KCSA Strategic Communications

Media Contacts
Raquel Cona
KCSA Strategic Communications

Primary Logo

Back to news